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Hepatitis B Virus Prevalence and Vaccination in Men Who 
Have Sex With Men in West Africa (CohMSM ANRS 
12324—Expertise France)
Ter Tiero Elias Dah,1,2,3,  Clotilde Couderc,3 Alou Coulibaly,4 Malan Jean-Baptiste kouamé,5 Mawuényégan Kouamivi Agboyibor,6 Issa Traoré,1  
Gwenaëlle Maradan,7 Daniela Rojas Castro,8 Ephrem Mensah,6 Camille Anoma,5 Bintou Dembélé Keita,4 Bruno Spire,7 and Christian Laurent3; on behalf of 
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1Association African Solidarité, Ouagadougou, Burkina Faso; 2Institut National de Santé Publique, Centre Muraz, Bobo Dioulasso, Burkina Faso; 3IRD, Inserm, Univ Montpellier, TransVIHMI, 
Montpellier, France; 4ARCAD-SIDA, Bamako, Mali; 5Espace Confiance, Abidjan, Côte d’Ivoire; 6Espoir Vie Togo, Lomé, Togo; 7Inserm, IRD, Univ Aix-Marseille, SESSTIM, Marseille, France; 8Coalition 
Plus, Pantin, France
Background. Although men who have sex with men (MSM) are at high risk of hepatitis B virus (HBV) infection, they do not 
have access to vaccination in West Africa, which is a highly endemic region. We investigated HBV prevalence and associated factors, 
as well as acceptability and difficulties of vaccination in MSM enrolled in an operational research program in Burkina Faso, Côte 
d’Ivoire, Mali, and Togo.
Methods. We followed up 779 MSM in 2015–2018. Participants who were negative for both hepatitis B surface antigen (HBsAg) 
and antibodies (anti-HBs) at enrollment were offered HBV vaccination. Factors associated with HBV infection were identified using 
logistic regression models.
Results. Overall, HBV prevalence was 11.2% (95% confidence interval [CI], 9.0%–13.6%). It was lower in Togo than in Côte 
d’Ivoire (2.7% vs 17.3%; adjusted odds ratio [aOR], 0.12; 95% CI, 0.02–0.28) and higher in participants with 6+ recent male sexual 
partners (21.0% vs 9.3%; aOR, 1.48; 95% CI, 1.12–1.97). Of 528 participants eligible for vaccination, 484 (91.7%) were willing to be 
vaccinated and received at least 1 dose (ranging from 68.2% in Abidjan to 96.4% in Bamako; P < .001). Of the latter, 390 (80.6%) re-
ceived 3 or 4 doses. The proportion of participants for whom the minimum required time between each dose was respected ranged 
from 10.9% in Bamako to 88.6% in Lomé (P < .001).
Conclusions. MSM in West Africa should be targeted more for HBV screening and vaccination. Although vaccination is well 
accepted by MSM, greater training of health care workers and education of MSM are required.
Keywords. Africa; hepatitis B; men who have sex with men; prevalence; vaccination.
Hepatitis B virus (HBV) infection is a major cause of severe 
morbidity (including liver cirrhosis and hepatocellular carci-
noma) and mortality (887 000 deaths worldwide in 2015) [1, 2]. 
Approximately 2 billion people have evidence of past or present 
HBV infection, representing almost 30% of the world’s popula-
tion [3]. Among them, 257 million are living with HBV infec-
tion, defined as testing positive for hepatitis B surface antigen 
(HBsAg) [1]. The prevalence of HBV infection is highest in the 
Western Pacific and in Africa (6.2% and 6.1%, respectively).
In Africa, HBV prevalence has mainly been reported in the 
general population and blood donors. Data for specific groups 
are still needed to obtain a thorough understanding of the local 
epidemiology of HBV infection and to develop a suitable stra-
tegic plan [4]. Men who have sex with men (MSM) are at high 
risk of acquisition and transmission of sexually transmitted 
infections (STIs) including HBV infection. Preliminary reports 
suggest that HBV prevalence in MSM is not very different than 
that in the general population (eg, 13.9% vs 11.1% in Senegal, 
8.0% vs 5.2% in Kenya, and 3.3% vs 7.2% in Tanzania), but this 
remains to be confirmed [5–8]. An HBV incidence of 6.0 per 
100 person-years in MSM has also been reported in Kenya, 
highlighting the need for HBV prevention including vaccina-
tion in this population [6].
Vaccination against HBV infection is a key element of pre-
vention and has been progressively scaled up in African coun-
tries thanks to its inclusion in the World Health Organization 
(WHO)–supported Expanded Program on Immunization in 
1991 [9]. However, this program focuses on children under 
5 years of age, and most adults today (ie, born before the era of 
HBV vaccination) have not been vaccinated [10]. Unlike most 
MSM in northern countries, African MSM do not have access 
to HBV vaccination in the routine care setting [11, 12].
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
2 • ofid • Dah et al
In this context, we investigated (1) HBV prevalence and as-
sociated factors and (2) acceptability and difficulties of vaccina-
tion in MSM enrolled in an operational research program in 4 
countries in West Africa, which is a highly endemic region for 
hepatitis B.
METHODS
Study Setting and Design
The study was performed in MSM enrolled in the ongoing 
CohMSM prospective cohort study, which was designed to 
assess the feasibility and interest of implementing a quar-
terly global HIV prevention care intervention in this key 
population (registered with ClinicalTrials.gov, number 
NCT02626286). MSM were recruited and followed up be-
tween June 2015 and June 2018 in 4 community-based clinics 
already providing MSM-specific prevention, care, and sup-
port in Bamako (Mali), Abidjan (Côte d’Ivoire), Ouagadougou 
(Burkina Faso), and Lomé (Togo). Eligibility criteria were as 
follows: aged 18 years or older, reporting at least 1 episode of 
anal intercourse with another man in the previous 3 months, 
and being HIV negative or having discovered HIV infection 
at enrollment. At enrollment and during the intervention’s 
quarterly follow-up visits, participants benefited from clinical 
examination, HIV testing, screening and treatment for other 
STIs (using the syndromic approach), and individualized 
peer-based support. They also received condoms and 
lubricants. MSM who tested HIV positive at enrollment were 
invited to initiate antiretroviral therapy (ART) immediately. 
MSM were also tested for hepatitis B, hepatitis C, and syph-
ilis at enrollment. Screening for HBsAg was performed using 
the CTK Biotech assay (San Diego, CA) in Bamako, the Abon 
Biopharm assay (Hangzhou, China) in Abidjan, and the SD 
Bioline assay (Gyeonggi-Do, South Korea) in Ouagadougou 
and Lomé. When the HBsAg result was negative, antibodies 
to hepatitis B surface (anti-HBs) were tested for using the 
CTK Biotech assay in Bamako and Ouagadougou, the Abon 
Biopharm assay in Abidjan, and the Dia Source assay (Louvin 
La Neuve, Belgium) in Lomé. Participants who tested posi-
tive for HBsAg were referred to national specialized care serv-
ices for further investigations and care. HIV/HBV-coinfected 
participants were offered tenofovir disoproxil fumarate (TDF) 
plus lamivudine (3TC) or emtricitabine (FTC) as part of ART. 
Vaccination against hepatitis B was part of the comprehensive 
intervention and was offered free of charge to participants who 
tested negative for both HBsAg and anti-HBs. Like the other 
interventions’ components, HBV vaccination was promoted 
by both physicians and peer educators. Hepatitis B vaccine 
was administered as a 3-dose regimen (day 0, month 1, and 
month 6) or, from November 2016, as a 4-dose regimen (day 
0, day 7, day 21, and month 12). Specific appointments were 
given outside the usual quarterly follow-up visits if needed. 
Vaccination status was assessed at every visit using participant 
and/or study site medical records. Finally, sociodemographic 
and behavioral data were collected at enrollment using a 
standardized face-to-face questionnaire administered by 
trained research assistants.
Statistical Analyses
HBV infection was defined as testing positive for HBsAg. The 
95% confidence intervals (CIs) of the prevalence rates of HBV 
infection were computed using the binomial method. Factors 
associated with HBV infection were identified using logistic 
regression models. Potential determinants to be tested were 
selected a priori on the basis of existing literature about hepa-
titis B. All variables associated with HBV infection with P < .20 
in univariate analyses were included in the complete multivar-
iate model. A backward procedure was used to determine the 
final model. The goodness of fit of models was assessed using 
the Hosmer-Lemeshow test.
The proportions of vaccinated participants were compared 
between the study sites using the Fisher exact test. The vac-
cination schedule was assessed in participants who received 
3 or 4 doses of vaccine. For the 3-dose regimen, the min-
imum required time was 21 days between the first and second 
doses and 4 months between the second and third doses. For 
the 4-dose regimen, the minimum required time was 6 days 
between the first and second doses, 12  days between the 
second and third doses, and 4 months between the third and 
fourth doses.
For all calculations, statistical significance was defined at 
P < .05. All statistical analyses were performed using Stata soft-
ware (version 13; Stata Corp LP, College Station, TX).
Ethical Considerations
The study protocol was approved by the national ethics 
committees of Mali, Côte d’Ivoire, Burkina Faso, and Togo, 
and the institutional ethics committee of the French Institut de 
Recherche pour le Développement. All participants provided 
written informed consent.
RESULTS
Study Population
Of the 787 MSM enrolled in the CohMSM study, 779 (99.0%) 
were tested for HBsAg and were included in the present anal-
ysis (Figure 1). Participant characteristics are shown in Table 
1. Three hundred four participants (39.0%) were enrolled in 
Bamako, 173 (22.2%) in Abidjan, 156 (20.0%) in Ouagadougou, 
and 146 (18.8%) in Lomé. Overall, the median age (interquartile 
range [IQR]) was 23.8 (21.4–27.4) years. Most participants had 
a secondary or higher educational level (82.2%) and were single 
(81.4%). Participants mainly self-defined as bisexual (64.1%) or 
homosexual/gay (30.8%). Approximately half perceived them-
selves as a man/boy, and 33.8% as both a man and a woman. 
The majority (53.5%) were sexually attracted to both men and 
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women. STI risky behaviors were common, as reflected by the 
high proportions of participants reporting unsystematic condom 
use during insertive anal sex (32.5%), unsystematic condom use 
during receptive anal sex (39.4%), or involvement in transac-
tional sex with male partners (33.0%). As a potential result of 
these behaviors, 14.1% of participants had at least 1 symptomatic 
STI at enrollment, and 23.7% had a history of symptomatic STIs 
in the previous 12 months. One hundred fifty-nine participants 
tested HIV positive at enrollment (20.4%).
HBV Infection
Eighty-seven of the 779 participants tested were HBsAg pos-
itive, giving an overall prevalence of HBV infection of 11.2% 
(95% CI, 9.0%–13.6%). Specifically, prevalence was 17.3% (95% 
CI, 12.0%–23.8%) in Abidjan, 11.8% (95% CI, 8.4%–16.0%) in 
Bamako, 10.9% (95% CI, 6.5%–16.9%) in Ouagadougou, and 
2.7% (95% CI, 0.7%–6.9%) in Lomé. HBV prevalence was sig-
nificantly lower in Lomé than in Abidjan in both univariate and 
multivariate analyses (odds ratio [OR], 0.13; 95% CI, 0.05–0.39; 
P  <  .001; and adjusted OR [aOR], 0.12; 95% CI, 0.02–0.28; 
P = .001) (Table 2). By contrast, the difference between Abidjan 
and both Bamako and Ouagadougou did not reach statistical 
significance in either analysis.
HBV prevalence was 9.3% (95% CI, 7.0%–11.5%) and 21.0% 
(95% CI, 12.9%–29.1%) in participants reporting, respectively, 
a maximum of 5 and a minimum of 6 male sexual partners in 
the prior 6 months. HBV prevalence was significantly higher in 
the latter in both univariate and multivariate analyses (OR, 1.37; 
95% CI, 1.14–1.65; P = .001; and aOR, 1.48; 95% CI, 1.12–1.97; 
P = .007).
In univariate analysis, HBV infection was also associated 
with gender identity and transactional sex with male partners. 
However, these relationships did not remain in multivariate 
analysis.
HBV prevalence was not significantly different between 
HIV-positive (14.5%; 95% CI, 9.4%–20.9%) and HIV-negative 
participants (10.3%; 95% CI, 8.0%–13.0%). However, the statis-
tical power was only 33%.
779 MSM screened for HBsAg 
8 MSM not screened for 
HBsAg
692 MSM tested HBsAg–
87 MSM tested HBsAg+
528 MSM tested anti-HBs–
390 MSM with 3 or 4 doses of vaccine
484 MSM initiated HBV vaccination
178 MSM with minimum required time 
between each dose
154 MSM tested anti-HBs+
10 MSM with missing data 
for anti-HBs
44 MSM not vaccinated
94 MSM with 1 or 2 doses of 
vaccine only
212 MSM without minimum
required time between each
dose
787 MSM enrolled in CohMSM
Figure 1. Flowchart of the HBV study (CohMSM study, West Africa, 2015–2018).
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Table 2. Factors Associated With HBV Infection in the 779 MSM Participants Using Logistic Regressions (CohMSM Study, West Africa, 2015–2018)
HBsAg+ Univariate Analysis Multivariate Analysis
 n (%) OR (95% CI) P aOR (95% CI) P
City        
 Abidjan 30 (17.3%) 1   1   
 Bamako 36 (11.8%) 0.64 (0.38–1.08) .096 0.72 (0.36–1.08) .246
 Ouagadougou 17 (10.9%) 0.58 (0.31–1.10) .098 0.65 (0.33–1.22) .230
 Lomé 4 (2.7%) 0.13 (0.05–0.39) <.001 0.12 (0.02–0.28) .001
Age, y        
 ≤25 51 (10.9%) 1      
 >25 35 (11.3%) 1.05 (0.66–1.65) .844    
Education level        
 Less than secondary school 18 (14.4%) 1      
 Secondary school 39 (12.3%) 0.84 (0.46–1.53) .562    
 University 22 (8.4%) 0.54 (0.28–1.05) .071    
Marital status        
 Married/free union 11 (8.9%) 1  .371    
 Single/divorced/separated/widower 67 (11.7%) 1.16 (0.83–1.63)     
Self-definition of sexual orientation        
 Bisexual/heterosexual 50 (10.2%) 1      
 Homosexual/gay/transsexual/transgender 35 (13.6%) 1.39 (0.87–2.20) .164    
Gender identity        
 A man/a boy 30 (8.0%) 1  .010    
 Much more a woman/both a man and a woman 53 (13.9%) 1.86 (1.16–2.98)     
Sexual attraction        
 To men 43 (13.7%) 1      
 To men and women/to women 42 (9.2%) 0.80 (0.64–1.00) .053    
Condom use during insertive anal sexa        
 Always 24 (8.5%) 1      
 Sometimes 42 (9.6%) 1.14 (0.60–2.17) .680    
 No insertive anal sex 18 (13.7%) 1.41 (0.95–3.06) .072    
Condom use during receptive anal sexa        
 Always 19 (10.0%) 1      
 Sometimes 40 (13.2%) 1.38 (0.77–2.45) .279    
 No receptive anal sex 25 (9.1%) 0.91 (0.48–1.69) .756    
Received payment (whether financial or other) for transactional 
sex with male partnersa
       
 Never 48 (9.3%) 1      
 Sometimes/always 36 (14.2%) 1.27 (1.00–1.60) .044    
Provided payment (whether financial or other) for transactional 
sex with male partnersa
       
 Never 68 (10.1%) 1      
 Sometimes/always 16 (17.2%) 1.36 (1.01–1.83) .041    
Group sex with male partners        
 Never 61 (10.8%) 1      
 At least once 23 (11.3%) 1.02 (0.79–1.32) .851    
Group sex with female partners        
 Never 81 (10.9%) 1      
 At least once 3 (13.0%) 1.23 (0.36–4.23) .741    
No. of male sexual partnersa        
 1–5 59 (9.3%) 1   1   
 ≥6 21 (21.0%) 1.37 (1.14–1.65) .001 1.48 (1.12–1.97) .007
STI        
 No 75 (11.2%) 1      
 Yes 11 (10.0%) 0.88 (0.45–1.71) .704    
STI within the previous 12 mo        
 No 61 (10.2%) 1      
 Yes 25 (13.7%) 1.40 (0.85–2.30) .189    
Syphilis        
 No 86 (11.2%) 1      
 Yes 1 (11.1%) 0.99 (0.12–8.03) .995    
HIV        
 No 64 (10.3%) 1   1   
 Yes 23 (14.5%) 1.47 (0.88–2.45) .141 1.18 (0.67–2.07) .574
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; STI, sexually transmitted infection.
aWithin the previous 6 months.
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HBV Vaccination
Of the 692 HBsAg-negative participants, 528 (76.3%) were 
also negative for anti-HBs and were eligible for HBV vaccina-
tion (Figure 1). Of the latter, the median follow-up time (IQR) 
was 21.1 (13.3–25.3) months. Four hundred eighty-four eligible 
participants (91.7%) were willing to be vaccinated and received 
at least 1 dose of vaccine, including 214 of 222 participants 
(96.4%) in Bamako, 122 of 130 participants (93.8%) in 
Ouagadougou, 105 of 113 participants (92.9%) in Lomé, and 
43 of 63 participants (68.2%) in Abidjan. The proportion of 
participants who initiated HBV vaccination was significantly 
lower in Abidjan than in the other 3 study sites (68.2% vs 94.8%; 
P <  .001). Of the 44 eligible participants who did not initiate 
vaccination, 19 (43.2%) did not come back for any planned 
follow-up visit (7 in Lomé, 6 in Bamako, 3 in Ouagadougou, 
and 3 in Abidjan), 4 (9.1%) were followed up for a maximum 
of 4 months (all in Abidjan), and 21 (47.7%) were followed up 
for more than 4 months (13 in Abidjan, 5 in Ouagadougou, 2 in 
Bamako, and 1 in Lomé).
Of the 484 participants who initiated vaccination, 390 
(80.6%) received 3 or 4 doses, including 88 of 105 participants 
(83.8%) in Lomé, 174 of 214 participants (81.3%) in Bamako, 
98 of 122 participants (80.3%) in Ouagadougou, and 30 of 43 
participants (69.8%) in Abidjan. The proportion of participants 
with 3 or 4 doses of vaccine tended to be lower in Abidjan than 
in the other 3 study sites, but this difference did not reach statis-
tical significance (69.8% vs 81.6%; P = .060).
In the 390 participants who received 3 or 4 doses of vac-
cine, the minimum required time between each dose was 
respected for only 178 participants (45.6%), including 78 of 88 
participants (88.6%) in Lomé, 65 of 98 participants (66.3%) in 
Ouagadougou, 16 of 30 participants (53.3%) in Abidjan, and 
19 of 174 participants (10.9%) in Bamako. The proportion of 
participants for whom the minimum required time between 
each dose of vaccine was respected was significantly lower in 
Bamako than in Abidjan, Ouagadougou, or Lomé (P < .001 for 
all 3 comparisons).
DISCUSSION
This multicountry study showed that, overall, the prevalence of 
HBV infection is high and that HBV vaccination is well accepted 
in MSM living in West Africa. However, it also highlighted that 
the vaccination schedule was not respected in a high proportion 
of participants. In addition, large discrepancies with regard to 
outcomes were observed between the study countries (Burkina 
Faso, Côte d’Ivoire, Mali, and Togo).
The prevalence of HBV infection differed between the study 
sites, being high in Abidjan (17.3%), Bamako (11.8%), and 
Ouagadougou (10.9%), but unexpectedly low in Lomé (2.7%). 
Our figure for Lomé was, however, in line with recent data in 
MSM in Togo (3.4%; 95% CI, 0.9%–5.9%) [13]. HBV prevalence 
rates in the first 3 study sites were among the highest reported 
to date in African MSM, whereas that for Lomé was among the 
lowest [5–7].
Compared with national estimations for the general popu-
lation found in a systematic review of data published between 
1965 and 2013 (9.4%; 95% CI, 8.7%–10.1% in Côte d’Ivoire; 
13.1%; 95% CI, 12.7%–13.5% in Mali; 12.1%; 95% CI, 11.7%–
12.4% in Burkina Faso; and 10.9%; 95% CI, 7.5%–15.6% in 
Togo) [8], the HBV prevalence rates in our study sites were 
higher (Abidjan), similar (Bamako and Ouagadougou), or 
lower (Lomé). However, it is worth noting that data in the sys-
tematic review for the general population in Togo came from 
only 1 study with 230 participants, whereas data for the other 
3 countries reflected thousands and even tens of thousands of 
participants included in 7 or 8 studies. In Ouagadougou, our 
HBV prevalence was also comparable with recent data in a rep-
resentative sample of men (10.5%; 95% CI, 9.6%–11.4%) [14].
A lower HBV prevalence in Togo than in other West African 
countries has also been reported in other populations. For 
instance, HBV prevalence was 5.2%, 10.1%, and 12.3% in 
HIV-infected patients in Togo, Côte d’Ivoire, and Senegal, re-
spectively (P  =  .02) [15]. In prisoners, HBV prevalence was 
10.9% in Togo and 14.1% in Senegal, but the difference was not 
statistically significant (P = .21) [16]. In our study, the large dis-
crepancy between Lomé and the other 3 study sites is, however, 
unclear and merits further investigation.
The small HBV prevalence differences between our study 
population and the general population in Burkina Faso, 
Côte d’Ivoire, and Mali suggest that most HBV infections in 
MSM occurred during childhood. However, the association 
found in our study between HBV infection and the number 
of male sexual partners in the prior 6  months suggests that 
sexual transmission is responsible for an additional number 
of infections in this population. Fortunately, HBV acquisi-
tion in adulthood progresses to chronic infection in less than 
5% of cases, as compared with 95% for HBV acquisition in 
childhood [3]. Nevertheless, as well as the consequences for 
MSM themselves, these acute infections can be transmitted 
to women because most African MSM also have hetero-
sexual relationships [17, 18], something indirectly confirmed 
by the characteristics on sexual orientation, gender identity, 
and sexual attraction reported by our participants. In addi-
tion to education on prevention measures (ie, reduction of the 
number of sexual partners and use of condoms), HBV vacci-
nation should therefore be proposed to MSM in Africa (as is 
already the case in northern countries), especially those most 
at risk of sexual exposure (eg, MSM with a high number of 
male sexual partners). Vaccination of MSM is important for 
eliminating viral hepatitis [19]. The high proportions of MSM 
willing to be vaccinated and who received at least 1 (91.7%) or 
3 (80.6%) doses of vaccine suggest good acceptability in this 
vulnerable population.
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In our study, HBV vaccination was hindered by organiza-
tional constraints, especially in Abidjan. More specifically, vac-
cination in Abidjan was administered to participants only at set 
times on set days by the team of the Institut National d’Hygiène 
Publique, initially in the study site clinic, and then in the clinic 
of the Institut National d’Hygiène Publique. By contrast, vacci-
nation could be administered to participants at any moment by 
the study medical teams in Bamako, Lomé, and Ouagadougou. 
Temporary stock-outs of vaccines also hampered their ad-
ministration, for instance, in Bamako and Ouagadougou. Our 
findings suggest that vaccination must be available at any mo-
ment in clinics focusing on MSM care. Furthermore, the vac-
cination schedule was impeded, especially in Bamako, because 
(1) some participants did not attend the specific appointment 
(ie, outside the usual quarterly follow-up visits), particularly at 
month 1 for the second dose of the 3-dose regimen (the most 
commonly used), and therefore received it at month 3, and (2) 
some physicians thought the third dose should be administered 
at month 6, independent of the actual timing of the second 
dose. Our results suggest that health care workers providing 
HBV vaccination need further training, especially with regard 
to scheduling doses. Education of MSM is also required.
The main strength of this study is that HBV prevalence and 
vaccination were investigated in MSM enrolled and followed up 
in 4 different West African contexts. This allowed us to high-
light differences in these outcomes between the study countries. 
However, our findings should be interpreted taking into ac-
count the following limitations. First, the study was performed 
on a convenience sample of MSM attending MSM-friendly 
clinics. Accordingly, they might not be fully representative of the 
global MSM community in the 4 study countries. Second, HBV 
screening was only performed using rapid tests, and individual 
national programs used tests from different manufacturers. Third, 
we were not able to investigate the determinants of vaccination 
acceptability as few participants did not agree to be vaccinated.
CONCLUSIONS
At a time where many West African countries are starting either to 
conceive or implement their national program against viral hepa-
titis, this study underlines the need to pay special attention to MSM 
for HBV screening, care, and vaccination activities. HBV vaccina-
tion is well accepted by MSM in the region, but greater training of 
health care workers and education of MSM are required.
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